British Columbia University has signed a licensing agreement with Commonsense for a treatment of asthma and other allergic conditions.
Commonsense, a subsidiary of biopharmaceutical company PureTech Health, today licensed research from British Columbia University (UBC) for a therapy to prevent asthma and other allergic diseases that present in childhood.
The technology consists of a live biotherapeutic product that relies on the microbiome. It is expected to complement Commonsense’s existing pipeline of therapeutic programs aimed at nurturing a healthy human gut early in life.
The technology was developed by Brett Finlay, professor of biochemistry and molecular biology at UBC, and…
